CORT
Corcept Therapeutics Incorporated · Healthcare · Medical - Pharmaceuticals
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 73.42K | $8.07M | +1 | n/a |
| Q2 2026 | 113 | +10 | 52.52M | $4.57B | +17 | −8 |
| Q1 2026 | 107 | -4 | 51.80M | $2.09B | +8 | −13 |
| Q4 2025 | 112 | 0 | 56.18M | $1.96B | +1 | n/a |
| Q3 2025 | 18 | -2 | 41.55M | $3.45B | +1 | −4 |
| Q2 2025 | 18 | +1 | 38.50M | $2.83B | +1 | n/a |
| Q1 2025 | 14 | +1 | 15.71M | $1.80B | +1 | n/a |
| Q4 2024 | 13 | 0 | 16.40M | $826.20M | n/a | n/a |
| Q3 2024 | 12 | -1 | 13.66M | $632.44M | n/a | −1 |
| Q2 2024 | 13 | n/a | 13.78M | $447.82M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 73.38K | -3.8% | $8.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 42 | New | $4,788 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| TD Waterhouse Canada Inc. | $4,788 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 347 holders, 79.01M shares, $2.83B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 6.65K sh · $761,717
Director · 3.05K sh · $351,476
Director · 300 sh · $34,889
Officer · 15.84K sh · $1.84M
Officer · 4.74K sh · $552,869
Officer · 8.74K sh · $1.02M
Officer · 4.45K sh · $514,389
Officer · 5.15K sh · $600,063
Officer · 1.10K sh · $125,973
Officer · 2.09K sh · $241,412
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology